In an effect to develop for more selective neuronal nicotinic acetylcholine receptor analgesics that have less toxicity and adverse side effects relative to epibatidine, three new classes of epibatidine analogues were synthesized and evaluated in vitro as potential potent selective nAChR ligands. Specifically, three analogues of epibatidine were synthesized to explore the structure-activity relationships of epibatidine relative to neuromuscular blocking activity as well as nAChRs. Both quaternary epibatidine analogues 2 and bis-epibatidine derivative 3 exhibited high binding affinity relative to nicotine. In addition, a new series of 2-(hydroxyalkylpyridyl)-7-azabicyclo[2.2.1]heptane derivatives were synthesized and evaluated as potential ligands for nicotinic acetylcholine receptors. Moreover, two rigid 2-acetoxy-7-azabicyclo[2.2.1]heptane analogues have been prepared to study the binding conformation of acetylcholine at the active sites of the nicotinic acetylcholine receptors.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a major dose-limiting side effect of several anticancer drugs. The prevalence of CIPN ranges from one-third to two-thirds of cancer patients. CIPN can persist for months to years after completion of chemotherapy. Despite the efficacious use of paclitaxel in the treatment of tumors, it can induce many sensory symptoms, such as paresthesia, numbness, tingling and burning pain, and mechanical and cold allodynia, which typically are present in the hands and feet. Similar to other types of chronic pain, paclitaxel-induced CIPN is comorbid with depression and anxiety in cancer survivors, and paclitaxel induces changes in affect-like behavior in cancer-free animal models, suggesting that paclitaxel can cause long-lasting changes in mood, reducing the quality of life. While adjuvant therapies, such as duloxetine, tricyclic antidepressants, and gabapentin are prescribed to treat CIPN symptoms, none of these compounds can consistently reverse or prevent the development of CIPN. With no FDA-approved medication to treat CIPN, the purpose of the dissertation was to: i) characterize and develop a mouse model of paclitaxel-induced CIPN, ii) identify putative targets for CIPN treatment, and iii) test novel compounds for their ability to prevent and reverse CIPN in C57BL/6J mice. In the first Aim, we demonstrate that paclitaxel induces time- and dose-dependent hypersensitivity (mechanical and cold), which is potentiated by combination therapy with the chemotherapeutic carboplatin. In addition, paclitaxel-treated mice show changes in affect-like behaviors (anxiety-like, depression-like). In the second Aim, we used the prototypic nicotinic receptor (nAChR) agonist nicotine to reverse or prevent paclitaxel-induced mechanical hypersensitivity and degeneration of Intra-Epidermal Nerve Fibers (IENFs). Further, we discovered that nicotine’s antinociceptive effects in this mouse model of CIPN are mediated by the nicotinic receptor subtype α7. The third Aim used genetic and pharmacological approaches to dissect the role of α7 on the development and maintenance of paclitaxel-induced CIPN. Null mutant α7 mice (KO) hastens the onset, increases the magnitude, and delays the recovery of paclitaxel-induced mechanical hypersensitivity, as compared to littermate wildtype controls, whereas the selective α7 silent agonist R-47 to reverses and prevents paclitaxel-induced CIPN in C57BL/6J mice. We also examined the impact of R-47 on the paclitaxel-induced reduction of intraepidermal nerve fiber (IENF), as well as microglial morphology in the dorsal horn of the spinal cord. The data show that R-47 prevents paclitaxel-induced changes in microglial morphology and mechanical hypersensitivity behavior, without producing tolerance upon repeated administration. Finally, R-47 induces preference using the conditioned place test in paclitaxel-treated mice but vehicle-treated animals, suggesting that R-47 is a viable candidate for ongoing, spontaneous pain, with limited risk of abuse potential. Overall, these results support that the α7 nAChR subtype is an important target for the treatment and prevention of CIPN.

Nicotine, the major psychoactive ingredient of tobacco smoke, underlies numerous effects by activating neuronal nicotinic acetylcholine receptors. Both in vitro and in vivo studies suggest that nicotine is neuroprotective and improves cognitive performance. Epidemiology studies show that smoking is negatively correlated with the incidence of Parkinson's disease and Alzheimer's disease. Postmortem research and neuroimaging studies show that loss of nicotinic binding sites in the brain is the major feature of neurodegenerative diseases related to dementia and cognitive impairment. Caloric restriction, a regimen that extends the lifespan in all mammalian species studied so far including rodents and primates, is a highly regulated response to food deprivation. It is believed that the longevity effect of caloric restriction is mediated by SIRT1, a NAD-dependent deacetylase, and its related genes. Nicotine's effect on body weight could also lead to weight loss by decreasing caloric absorption consumption. The goal of this study was to find the possible correlation between nicotine's effects and the activation of SIRT1 and its related genes. Using beta2-/- mice that lack high affinity beta2 nicotinic acetylcholine receptors (nAChRs), we first demonstrated that beta2* nAChRs do not directly regulate expression of survival genes. However, we found that loss of beta2* nAChRs could result in augmented cellular stress, which indirectly increased expression of SIRT1, Nampt, and Ku70, possibly as an adaptive response to provide protection against neurodegeneration. We also found that loss of endogenous activation of beta2* nAChRs had less effect on synaptic connections but strongly impaired survival of hippocampal GABAergic neurons. To activate beta2* nAChRs in normal mice, we administered nicotine through drinking water. In a short-term exposure study, we determined the dose of nicotine to be used in young adult mice, and found that chronic nicotine treatment was anxiolytic, decreased caloric consumption, increased nAChR binding sites, and most importantly, increased expression of SIRT1 and its related genes. Finally, we compared long-term nicotine treatment with caloric restriction in middle-aged mice to examine their effects to brain aging, and our results indicated that in mice long term caloric restriction and nicotine treatment both tend to improve memory in aging mice, but appear to act through different mechanisms.

Οι α7 και α9 υπομονάδες των νικοτινικών υποδοχέων ακετυλοχολίνης (nAChRs) είναι οι μόνες, ανάμεσα σε μια μεγάλη ποικιλία υπομονάδων του ανθρώπινου nAChR, που σχηματίζουν ομοπενταμερείς υποδοχείς. Για την θεραπεία διαφόρων νευρολογικών διαταραχών αλλά και άλλων ασθενειών, όπου εμπλέκονται οι α7 και α9 nAChRs, απαιτούνται φαρμακευτικές ουσίες που θα στοχεύουν ειδικά σε έναν υπότυπο των nAChRs. Για τον σχεδιασμό τέτοιων φαρμάκων είναι ουσιώδης η διαλεύκανση σε ατομικό επίπεδο της δομής του nAChR. Εντούτοις, η κρυστάλλωση ολόκληρων των διαμεμβρανικών υποδοχέων, αλλά ακόμη και η έκφραση και απομόνωσή τους, σε βαθμό που να επιτρέπει δομικές μελέτες, έχει αποδειχθεί δύσκολος στόχος. Η δυσκολία έγκειται κυρίως στην παρουσία υδρόφοβων διαμεμβρανικών περιοχών και στην μεγάλη ενδοκυττάρια περιοχή που θεωρείται ευκίνητη και ότι δεν έχει σταθερή διαμόρφωση. Στο πλαίσιο αυτό, στοχεύσαμε στην παραγωγή τμημάτων των α7 και α9 υπομονάδων του nAChR, που να είναι κατάλληλα για αναλυτικές δομικές μελέτες, σχεδιάζοντας κατασκευές για την έκφραση των εξωκυτταρικών περιοχών των δύο υπομονάδων ή και κολοβών διαμεμβρανικών μορφών της α7 υπομονάδας. Σε αυτές έχουν απαλειφθεί είτε τμήματα της μεγάλης ενδοκυτταρικής περιοχής, είτε ολόκληρη αυτή η περιοχή και μεγάλα τμήματα της διαμεμβρανικής περιοχής. Στο παρελθόν, είχε εκφραστεί η α7-ΕΚΠ στο ετερόλογο σύστημα έκφρασης Pichia pastoris και είχε οδηγήσει σε συσσωματώματα μεγάλου μοριακού βάρους, ενώ η έκφραση ενός μεταλλάγματος της α7-ΕΚΠ έδειξε σημαντική βελτίωση της υδροφιλικότητας του μορίου και σχηματισμό ολιγομερών κυρίως πενταμερών μορίων (Zouridakis et al. 2009). Σε αυτήν την εργασία, έχουμε επιτύχει να απομονώσουμε τα σχηματιζόμενα πενταμερή μόρια αυτού του μεταλλάγματος, εκμεταλλευόμενοι την ιδιότητα τους να εκλούονται σε μεγάλο εύρος συγκέντρωσης ιμιδαζολίου, κατά την χρωματογραφία συγγένειας. Ακόμη, η ενζυμική απογλυκοζυλίωση του μεταλλάγματος αυτού, βοήθησε στην περαιτέρω μείωση της ετερογένειας των απομονωμένων πενταμερών μορίων. Αν και ο αρχικός έλεγχος συνθηκών κρυστάλλωσης των γλυκοζυλιωμένων πενταμερών μορίων οδήγησε στον σχηματισμό μικροκρυστάλλων, δεν στάθηκε δυνατή η βελτιστοποίηση της ανάπτυξής τους. Η έκφραση της αγρίου τύπου εξωκυτταρικής περιοχής της α9 υπομονάδας του ανθρώπινου nAChR (α9wt) στο ετερόλογο σύστημα έκφρασης P. pastoris, οδήγησε στην παραγωγή κυρίως μονομερών μορίων που διαχωρίζονται εύκολα από τα σχηματιζόμενα ολιγομερή. Η μονομερής μορφή της α9wt έδειξε αξιοσημείωτη διαλυτότητα, σταθερότητα και ομοιογένεια καθώς και ικανότητα πρόσδεσης της α-μπουγκαροτοξίνης, έναν ειδικό ανταγωνιστή του μυικού και των ομοπενταμερών νευρικών nAChRs. Προκειμένου να υποβοηθηθεί η συναρμολόγηση των εκφραζόμενων α7 και α9 ΕΚΠ προς τον σχηματισμό πενταμερών μορίων, σχεδιάσαμε μεταλλάξεις που στηρίχθηκαν σε τρισδιάστατα μοντέλα ομολογίας (3D homology modelling) αυτών, χρησιμοποιώντας ως πρότυπο την κρυσταλλική δομή της ομόλογης, διαλυτής πρωτεΐνης δεσμεύσεως της ακετυλοχολίνης (AChBP) από το μαλάκιο Lymnaea stagnalis. Οι μεταλλαγές αυτές έγιναν είτε σε υδρόφοβα επιφανειακά αμινοξικά κατάλοιπα, με στόχο να αυξήσουμε την υδροφιλικότητα του μορίου, είτε σε κατάλοιπα που εντοπίζονται στις διεπιφάνειες μεταξύ δύο πρωτομερών, ώστε να ενισχύσουμε τις διαμοριακές αλληλεπιδράσεις και να υποβοηθήσουμε την συναρμολόγηση τους προς πενταμερή μόρια. Τα προκύπτοντα μεταλλάγματα έχουν ταύτιση αμινοξικής αλληλουχίας 70-95% με την αντίστοιχη του αγρίου τύπου και σε ορισμένες περιπτώσεις η έκφρασή τους στην P. pastoris οδήγησε στον σχηματισμό αλλά και την απομόνωση πενταμερών μορίων. Η σάρωση των μεταλλαγμάτων απέτυχε στην ανεύρεση κάποιας συνθήκης κρυστάλλωσής τους. Ωστόσο, ο αρχικός έλεγχος συνθηκών κρυστάλλωσης των μονομερών μορίων της α9wt είχε ως αποτέλεσμα τον προσδιορισμό διαφορετικών συνθηκών όπου σχηματίζονται πολλαπλοί κρύσταλλοι, τόσο για την γλυκοζυλιωμένη, όσο και την απογλυκοζυλιωμένη μορφή της. Επιπλέον, η βελτιστοποίηση αυτών των κρυστάλλων στην περίπτωση της γλυκοπρωτεΐνης, οδήγησε στο σχηματισμό μονοκρυστάλλων, που περιθλούν ακτίνες-Χ σε ικανοποιητική ανάλυση, καθιστώντας αυτούς τους κρυστάλλους ως υποσχόμενο υλικό για την επίλυση της δομής της άγριου τύπου α9 ΕΚΠ. Τέλος, η έκφραση στην κυτταρική σειρά εντόμων Sf9 με το σύστημα των βακιλοϊών της ολόκληρης α7 υπομονάδας του nAChR και των «κολοβών» διαμεμβρανικών μορφών της οδήγησε στην ορθή στόχευση των σχηματιζόμενων υποδοχέων στην κυτταροπλασματική μεμβράνη, ενώ οι φαρμακολογικές τους ιδιότητες προσεγγίζουν αυτές του φυσικού α7 υποδοχέα. Παρά το γεγονός ότι η έκφραση των κατασκευών αυτών είχε χαμηλή απόδοση και παρά τις δυσκολίες διαλυτοποίησης και απομόνωσής τους, ανάλυση με χρωματογραφία μοριακού αποκλεισμού, για τουλάχιστον δύο από τα διαμεμβρανικά μεταλλάγματα, δείχνει ότι οι διαλυτοποιημένες πρωτεΐνες έχουν σχηματίσει έναν πληθυσμό ολιγομερών της πρωτεΐνης ο οποίος πιθανότατα αντιστοιχεί σε πενταμερή μόρια. Τα παραπάνω, σε συνδυασμό με την απουσία της εύκαμπτης ενδοκυττάριας περιοχής, καθιστούν αυτά τα α7 μεταλλάγματα, εφόσον ξεπεραστούν οι δυσκολίες της απόδοσης της έκφρασης και της απομόνωσης τους, κατάλληλα για λειτουργικές και δομικές μελέτες. / The neuronal α7 and α9 subunits of the nicotinic acetylcholine receptor (nAChR) are the only amongst the known human nAChR subunits to form homopentamers, with five cholinergic ligand-binding sites. Elucidation of their crystal structure is essential in order to design highly specific drugs for treatment of several neurological diseases and disorders related to them and will serve as the prototype for understanding the structure of all other members of the ligandgated ion channel superfamily. Crystallisation of the intact receptors is a difficult task to fulfil, partially due to their hydrophobic transmembrane regions. Therefore, we aim at the expression of crystallisable human α7 and α9 extracellular domains (ECDs) or truncated α7 forms lacking either only their large and probably unordered intracellular domain or large parts of its transmembrane domain. Regarding the α7 ECD, expression of the wild type form in yeast Pichia pastoris led into formation of aggregates (Avramopoulou et al. 2004). Yet, a previously described mutant of this ECD (α7m10, Zouridakis et al. 2009) succeeded in the formation of oligomers, mostly corresponding to pentamers, due to improved solubility and subunit assembly of this mutant. In this study, we managed to isolate apparently pentameric assemblies of the various expressed oligomeric states, by optimizing its first-step purification procedure (metal affinity chromatography), using a narrow stepwise increase of imidazole concentrations. In order to further improve the protein homogeneity, we proceeded to the isolation of its deglycosylated pentameric form. The relatively low polydispersity of both the glycosylated and deglycosylated α7m10 ECDs, allowed for crystallization trials, which have resulted in microcrystallic formations. Further optimization of these microcrystals failed. As to the α9 ECD, expression of the wild type form in yeast Pichia pastoris led to the formation of both monomers and a variety of oligomers. The monomeric α9 ECD showed significant monodispersity, solubility and stability and exhibited binding ability of α- bungarotoxin, a specific nAChR antagonist. In order to facilitate the pentameric assembly and enhance the solubility of these α7 and α9 ECDs, we designed several mutants based on generated 3D homology models, using as template the crystal structure of the homologous soluble molluscan acetylcholine binding protein (AChBP). Several solvent accessible hydrophobic residues were replaced with more hydrophilic ones and some interface-located residues were mutated so as to facilitate the formation of additional inter-subunit interactions. The resulting mutants shared moderate and considerably high sequence identities (70-95%) with the wild type ECDs and in some cases, formation of pentamers was accomplished. Crystallisation screening for mutant ECDs failed in producing any hit. However, the pilot crystallisation trials of monomeric wild-type α9 ECD resulted the formation of plate-like multi crystals for both its glycosylated and deglycosylated forms. Further optimisation of these crystals succeeded in producing single crystals of the glycoprotein, to produce single crystals, which diffracted X-rays to satisfactory resolution, in a home source X-ray generator. Therefore, these crystals seem to be a promising material for solving the wild type α9 ECD structure. The intact and truncated α7 nAChRs under study were expressed in the Sf9/baculovirus system and showed surface receptor expression, while presenting near-native ligand-binding affinities for characteristic nAChR agonists and antagonists. Despite the low expression yield and solubilisation and purification difficulties, gel filtration analysis for at least two truncated mutants revealed the presence of a monodispersed oligomeric population, probably corresponding to pentamers. All these, taken together with the lack of the flexible large intracellular domain, render these α7 mutants, after overcoming the expression yield and purification difficulties, a suitable material for performing both functional and structural studies.

Diabetes, which is characterized by elevated plasma glucose, can have a devastating effect on peripheral nerves frequently leading to the clinical symptoms of neuropathy. Diabetic autonomic neuropathy (DAN) results from damage to autonomic nerves, and the most troubling forms of DAN often lead to cardiovascular abnormalities and premature death. Despite the prevalence of DAN and the impact to quality and life expectancy, the precise mechanisms underlying these pathologies are poorly understood. Recently, a new model for the onset of DAN was proposed where hyperglycemia-induced oxidative stress inactivates nicotinic acetylcholine receptors (nAChRs), the main receptor driving autonomic synaptic transmission at sympathetic ganglia. This inactivation leads to the depression of synaptic transmission, and consequently triggers the onset of autonomic neuropathy in diabetic mice. However, the source and pathways contributing to the elevation of reactive oxygen species (ROS) and oxidative stress remained unclear. In recent years it has been shown that the accelerated formation of advanced glycation end products (AGEs) and activation of their receptor (RAGE) in diabetes play a major role in the induction of oxidative stress in sensory nerve damage. Thus we hypothesized that the activation and up-regulation of RAGE during high glucose conditions is a major source of ROS production in sympathetic neurons leading to the inactivation of nAChRs and autonomic malfunction. In this thesis we show for the first time that RAGE is expressed in cultured sympathetic neurons and is also up-regulated during high glucose conditions. Our results further demonstrate that direct RAGE activation by its natural ligands leads to an increase in cytoplasmic ROS which in turn induces the inactivation of nAChRs in sympathetic neurons. We also report that high glucose-induced ROS generation and subsequent inactivation of nAChRs is prevented in sympathetic neurons from RAGE knock-out mice. The results of this dissertation suggest RAGE to be a pivotal source of ROS production leading to the functional deficits observed in sympathetic neurons during high glucose conditions.

abstract: Tobacco and alcohol are the most commonly abused drugs worldwide. Many people smoke and drink together, but the mechanisms of this nicotine (NIC) -ethanol (EtOH) dependence are not fully known. EtOH has been shown to affect some nicotinic acetylcholine receptors (nAChRs), which potentially underlies NIC-EtOH codependence. Ventral Tegmental Area (VTA) dopamine (DA) and γ-aminobutyric acid (GABA) neurons express different nAChR subtypes, whose net activation results in enhancement of DA release in the Prefrontal Cortex (PFC) and Nucleus Accumbens (NAc). Enhancement of DA transmission in this mesocorticolimbic system is thought to lead to rewarding properties of EtOH and NIC, clarification of which is relevant to public health and clinical diseases. The aim of this study was to elucidate pharmacological mechanisms of action employed by both NIC and EtOH through nAChRs in VTA neurons by evaluating behavioral, network, synaptic and receptor functions therein. It was hypothesized that VTA GABA neurons are controlled by α7 nAChRs on presynaptic GLUergic terminals and α6 nAChRs on presynaptic GABAergic terminals. NIC and EtOH, via these nAChRs, modulate VTA GABA neuronal function. This modulation may underlie NIC and EtOH reward and reinforcement, while pharmacological manipulation of these nAChRs may be a therapeutic strategy to treat NIC or EtOH dependence. This data demonstrates that in VTA GABA neurons, α7 nAChRs on GLUergic terminals play a key role in the mediation of local NIC-induced firing increase. α6*-nAChRs on GABA terminals enhances presynaptic GABA release, and leads to greater inhibition to VTA GABA neurons, which results in an increase VTA DA neuron firing via a disinhibition mechanism. Genetic knockout of these nAChRs significantly prevents EtOH-induced animal conditioned place preference (CPP). Furthermore, levo-tetrahydropalmadine (l-THP), a compound purified from natural Chinese herbs, blocks nAChRs, prevents NIC-induced DA neuronal firing, and eliminates NIC CPP, suggesting it as a promising candidate in a new generation of interventions for smoking cessation. Improved understanding of underlying mechanisms and development of new drugs will increase the number of successful quitters each year and dramatically improve the quality of life for millions suffering from addiction, as well as those around them. / Dissertation/Thesis / Doctoral Dissertation Neuroscience 2015

The prevailing view is that enhancement of dopamine (DA) transmission in the mesolimbic system leads to the rewarding properties of alcohol and nicotine (NIC). The mesolimbic DA system consists of DA neurons in the midbrain ventral tegmental area (VTA) that innervate the nucleus accumbens (NAc). DA neurotransmission is regulated by inhibitory VTA GABA neurons, whose excitability is a net effect of glutamate (GLU) and GABA neurotransmission that are modulated by NIC cholinergic receptors (nAChRs) on afferent terminals. We have previously demonstrated that VTA GABA neurons are excited by low-dose ethanol but are inhibited by moderate to high-dose ethanol, and they adapt to chronic ethanol, evincing marked hyperexcitability during withdrawal. The aim of this study was to evaluate the role of α6 nAChRs in ethanol effects on VTA GABA and DA neurons. In order to more conclusively demonstrate the role of α6 nAChRs in alcohol modulation in the VTA, we profiled the pharmacological interactions between ethanol and α6 nAChRs using recombinant α6 nAChRs in human epithelia (SH-EP1) cells and evaluated the effects of α6 nAChR antagonists on ethanol inhibition of GABA-mediated synaptic responses in dissociated GABA neurons of the VTA by recording mIPSCs; and assessed the effects of α6 nAChR antagonists on ethanol inhibition of VTA neurons, via eIPSCs on GABA neurons, sIPSCs on GABA neurons, and firing rate of DA neurons. We found that ethanol enhanced NIC currents in SH-EP1 cells via α6 nAChRs. Electrophysiology studies showed that superfusion of ethanol (5-30 mM) enhanced the frequency and amplitude of mIPSCs recorded in acutely dissociated VTA GABA neurons from GAD-GFP mice. Furthermore, the α6 nAChR antagonist α-conotoxin P1A (10 nM) prevented the ethanol-induced changes in mIPSC. In support, eIPSC experiments demonstrated that low doses of ethanol (1-5 mM) enhanced eIPSC peaks and decreased paired-pulse ratio, suggesting a presynaptic effect with ethanol. Alpha-conotoxin MII (α-CTX MII) blocked ethanol's effects on eIPSCs. This effect on VTA GABA neurons was also seen in sIPSCs, as ethanol decreased GABA firing rate. Similarly, the inhibition caused by ethanol was prevented by α-conotoxin P1A (10 nM). Additionally, CPP studies showed that α6 KO mice and WT mice treated with MEC, a non-competitive, non-α7 antagonist, did not show a preference for EtOH compartments that was found in WT mice. Taken together, these studies indicate that ethanol is acting through α6 nAChRs on GABA terminals to enhance GABA release, suggesting a possible mechanism of action of alcohol and nicotine co-dependence. Through these studies conducted to understand the role of α6 nAChRs in ethanol modulation, we hope to further outline how alcohol alters brain activity so that we can ultimately facilitate the development of therapies/medications for the treatment of alcoholism.

Alpha7 Neuronal nicotinic acetylcholine receptors (nAChRs) are involved in essential physiological functions and play a role in disorders such as Alzheimer’s disease. MD-354 (3-chlorophenylguanidine; 21), the first small–molecule negative allosteric modulator (NAM) at alpha7 nAChRs, served as a lead in developing structure–activity relationships for NAMs at a7 nAChRs. MD-354 (21) also binds at 5-HT3 receptors. Analogs of MD-354 with structural features detrimental to 5-HT3 receptor affinity were evaluated in patch-clamp recordings and an aniline N-methyl analog resulted in a more potent and selective NAM than MD-354. A new N-methyl series of compounds was synthesized in which the 3-position was replaced with different substituents considering their electronic, lipophilic, and steric nature. Comparative studies were initiated to investigate whether or not the MD-354 series and the N-methyl series bind in the same manner; 3D models of the extracellular domain of human alpha7 nAChRs were developed, allosteric sites identified, and docking studies conducted.

-- / The nicotinic acetylcholine receptors (nAChRs) are transmembrane proteins, composed of five subunits and belong to the superfamily of ligand gated ion channels The nAChRs are distinguished according to their topological and pharmacological characteristics in muscle and nervous type. Both the muscle and the nervous type are involved in the execution of many physiological functions (eg, nerve impulse transmission) but respectively in the pathogenesis of many diseases (eg Myasthenia Gravis,Parkinson's,Alzheimer's).This makes imperative the need to design drugs that target specific to each type of receptor. A prerequisite for achieving this objective is to study the structure of the extracellular regions of the receptor, as it is known that the specific areas are recognised by the cholinergic ligands and the abnormal antibodies. The α7 subunit of the human nicotinic acetylcholine receptor, can be used as a model for this study as It is expressed as a homopentamer. Wanting therefore to avoid the large and hydrophobic transmembrane regions of the receptor that would hinder the achievement of the objective, we focused on the extracellular domain (ECD) of the receptor .So, according to the above, a recombinant form of the extracellular region of the receptor was constructed and expressed previously in our laboratory (Zouridakis et al., 2009). The recombinant protein was (α7-mut10-myc-His), expressed in soluble form, in sufficient concentration and showed about three times greater affinity for I125-a-bgtx compared to the wild type (α7-ΔCDwt). Furthermore, studies of dynamic light scattering and electron microscopy confirmed the formation of homopentamer molecules. Moreover, the deglycosylated form of the protein displayed all these enhanced features, allowing the entry of crystallization experiments with both the glycosylated and the deglycosylated form. In order to further improve the specific mutant, new recombinant forms of the extracellular region of the α7 subunit of the nAChR were constructed. The recombinant forms were expressed with different expression tags in their N-or C-terminal in order to improve the folding of the molecule. The FLAG-α7-mut10-myc-His was produced in greater quantity and Ηts deglycosylated form differs significantly, indicating probably a more homogeneous protein population. Also, analysis of the molecule bygel filtration showed the predominant formation of a homopentamer molecule and the absence of high molecular weight aggregates. This protein, has enhanced features compared to the α7-mut10-myc-His and thus can proceed to crystallization trials. The second part of the study refers to the construction concateremers of the α7ECD. Σwo peptide linkers varying in their length were used. The mutant which carried the smaller linker (AGS)8, showed greater solubility compared to the more extended one (AGS)11.

Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that are necessary in memory and cognition. They are pentameric and consist of α and β subunits. They are most commonly heteromeric but, can sometimes be homomeric. nAChRs are activated by many ligands including nicotine (exogenous) and acetylcholine (endogenous).nAChRs are located on hippocampal interneurons. The interneurons, although sparse, control the synchronous firing of the pyramidal cells. However, the hippocampal interneuron structure and function is quite diverse and not fully characterized. Therefore, we sought to quantify nAChR subunit mRNA levels using real-time PCR of CA1 hippocampal interneurons.Surprisingly we found that the α3 and β2 mRNA subunits were the highest expressed and highest co-expressed subunits. Additionally, the α4 mRNA subunit was the lowest expressed of the subunits detected. The α4 subunit is one of the most pharmacologically targeted nAChR subunits and is found throughout the rest of the brain at much higher levels than the α3 mRNA subunit. Upon PCR analysis two subpopulations of the α3 and β2 subunits emerged: those that contained 3X more α3 than β2 and those that contained 3X more β2 than α3. Therefore, we hypothesized that two likely α3β2 nAChR stoichiometries are present in hippocampal interneurons. We differentiated their kinetic properties using electrophysiology.Additionally, like the α4 subunit, the α7 subunit is highly targeted in cognitive therapeutics. Since, the α7 subunit is the most characterized nAChR subunit, there are current efforts to develop allosteric modulators of the α7 subunit. The α7 subunit is found at moderate levels within hippocampal interneurons and remains a valid target. Current treatment options for Alzheimer's disease, and other dementias are limited and only mildly effective. Therefore, we sought to characterize the effect of 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2) on α7.Furthermore, there are no current methods to distinguish the α7 from the α7β2 nAChRs during whole cell electrophysiological recordings. Therefore, we also characterized the PAM-2 effect on α7β2 nAChRs. Our results highlight at least 2 ways PAM-2 can be used to differentiate α7 from the α7β2 during whole-cell recordings.